Imbruvica

FDA expands approved use of Imbruvica for chronic lymphocytic leukemia

Oplinc Fast Facts…

* CMS Releases Proposed 2015 Physician Fee Schedule Rule * The Sunshine Act And Open Payments

Belinostat/Beleodaq

On July 3, 2014, the U. S. Food and Drug Administration granted accelerated approval to belinostat (BELEODAQ, Spectrum Pharmaceuticals, Inc.) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).